Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
A phase 3 trial of Elranatamab, Lenalidomide in multiple myeloma, run by Pfizer, active and no longer recruiting.
Overview
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant is a phase 3 interventional study registered as NCT05317416 by Pfizer, with 854 participants enrolled, started 2022-03-25 and due to reach its primary completion in 2027-08-04. Interventions recorded: Elranatamab, Lenalidomide, Lenalidomide, Elranatamab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide
Shares Elranatamab, Lenalidomide, Pfizer (incl. Seagen), Multiple myeloma.
- TrialA Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Shares Elranatamab, Pfizer (incl. Seagen), Multiple myeloma.
- TrialMagnetisMM-3
Shares Elranatamab, Multiple myeloma.
- TrialSafety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Shares Lenalidomide, Multiple myeloma.
- TrialAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Shares Elranatamab, Multiple myeloma.
- TrialMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other
Shares Elranatamab, Pfizer (incl. Seagen), Multiple myeloma.
- TrialA Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama
Shares Elranatamab, Multiple myeloma.
- TrialBrentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Shares Lenalidomide, Pfizer (incl. Seagen).